Should we be surprised at the paucity of response to EGFR inhibitors? (Q37467394)

20 August 2017

1 reference

title

Should we be surprised at the paucity of response to EGFR inhibitors? (English)

1 reference

20 August 2017

Barry A Gusterson

1

1 reference

PubMed ID

19410197

20 August 2017

Keith D Hunter

series ordinal

2

1 reference

20 August 2017

1 May 2009

1 reference

Lancet Oncology Commission

20 August 2017

1 reference

20 August 2017

10

1 reference

20 August 2017

5

1 reference

20 August 2017

522-527

1 reference

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

The epidermal growth factor receptor pathway: a model for targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Autocrine secretion and malignant transformation of cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Survival of cancer cells is maintained by EGFR independent of its kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Isolation and structure of urogastrone and its relationship to epidermal growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

The effect of growth-promoting agents on replication and cell cycle withdrawal in cultures of epidermal keratinocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

EGFR enhances early healing after cutaneous incisional wounding

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

A serum factor after intestinal resection stimulates epidermal growth factor receptor signaling and proliferation in intestinal epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

EGF receptor signaling affects bcl-2 family gene expression and apoptosis after massive small bowel resection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

IKKalpha is required to maintain skin homeostasis and prevent skin cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Cellular localisation of human epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Ability of normal human keratinocytes that grow in culture in serum-free medium to be derived from suprabasal cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Increased EGF receptors on human squamous carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Peptide growth factors are multifunctional

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Biological significance of c-erbB family oncogenes in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Keratinocyte growth factor: effects on keratinocytes and mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Clinical implications of the mechanism of epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Physicochemical modelling of cell signalling pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

EGFR amplification and lack of activating mutations in metaplastic breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Predicting response of molecular targeted therapies: a still possible challenge?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970034-8

7 January 2021

10.1016/S1470-2045(09)70034-8

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19410197